ORTHOFIX MEDICAL INC. financials

OFIX CIK 0000884624

Source: EDGAR filings · Built 2026-06-02T03:43:32Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -2.04M -9.79M -106.66M -35.50M 153.00K 58.46M
EBITDA -4.11M -24.56M -86.05M 15.75M 21.28M 24.28M
Working Capital 246.37M 264.66M 255.22M 172.37M 163.69M 166.48M
Net Debt 121.82M 109.78M 101.09M -23.80M -64.68M -68.41M
Gross Margin 68.83% 68.28% 65.13% 73.18% 75.26% 74.94%
Operating Margin -9.90% -10.58% -18.63% -2.88% -1.79% -1.54%
Net Margin -11.21% -15.76% -20.28% -4.29% -8.26% 0.62%
Return on Equity (ROE) -20.49% -25.04% -25.29% -5.86% -11.39% 0.71%
Return on Assets (ROA) -10.84% -14.10% -16.36% -4.31% -8.05% 0.48%
Current Ratio 2.45× 2.57× 2.54× 3.06× 2.55× 2.60×
Debt-to-Equity 0.45× 0.38× 0.22× 0.08× 0.07× 0.08×
Effective Tax Rate -1.52% -1.71% -1.83% -11.54% -184.39% 783.97%
Cash Conversion Ratio -0.36× -0.20× 0.30× 0.58× -0.48× 29.51×
Accruals Ratio -0.15× -0.17× -0.11× -0.02× -0.12× -0.14×
SBC % of Revenue 3.49% 4.06% 4.78% 4.00% 3.32% 3.99%
CapEx Coverage 0.94× 0.72× -0.75× -0.48× 1.01× 4.70×
Free Cash Flow Per Share $-0.05 $-0.26 $-2.90 $-1.77 $0.01 $3.01

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 330.62×
P/FCF 3985.90× 14.26×
FCF Yield 0.03% 7.01%
EV / EBITDA 24.77× 25.94× 31.57×
P/S 0.73× 0.84× 0.67× 0.90× 1.33× 2.05×
P/B 1.34× 1.34× 0.84× 1.23× 1.83× 2.34×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 822.31M 799.49M 746.64M 460.71M 464.48M 406.56M
Cost of Goods and Services Sold 256.30M 253.61M 260.37M 123.54M 114.91M 101.89M
Gross Profit 566.02M 545.88M 486.27M 337.17M 349.56M 304.67M
Research and Development Expense 65.85M 73.64M 80.23M 49.06M 49.62M 39.06M
Selling, General and Administrative Expense 554.33M 532.52M 530.39M 308.78M
Operating Income (Loss) -81.43M -84.62M -139.11M -13.27M -8.31M -6.27M
Income Tax Expense (Benefit) 1.38M 2.12M 2.72M 2.04M 24.88M -2.88M
Net Income (Loss) Attributable to Parent -92.19M -126.00M -151.40M -19.75M -38.38M 2.52M
Earnings Per Share, Basic $-2.33 $-3.30 $-4.12 $-0.98 $-1.95 $0.13
Weighted Average Number of Shares Outstanding, Basic 39.60M 38.13M 36.73M 20.05M 19.69M 19.27M
Earnings Per Share, Diluted $-2.33 $-3.30 $-4.12 $-0.98 $-1.95 $0.13
Weighted Average Number of Shares Outstanding, Diluted 39.60M 38.13M 36.73M 20.05M 19.69M 19.39M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 82.03M 83.24M 33.11M 50.70M 87.85M 96.29M
Assets, Current 416.85M 433.29M 420.44M 255.99M 269.52M 270.38M
Assets 850.65M 893.29M 925.32M 458.63M 476.62M 525.86M
Long-term Debt 157.01M 94.36M
Liabilities, Current 170.48M 168.63M 165.22M 83.62M 105.83M 103.90M
Long-term Debt, Excluding Current Maturities 157.39M 157.01M 93.11M
Liabilities 400.61M 390.17M 326.58M 121.77M 139.69M 169.00M
Stockholders' Equity Attributable to Parent 450.04M 503.12M 598.73M 336.86M 336.93M 356.86M
Common Stock, Shares, Outstanding 39.83M 38.49M 37.16M 20.16M 19.84M 19.42M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 33.35M 25.79M -45.75M -11.54M 18.48M 74.27M
Payments to Acquire Property, Plant, and Equipment 60.26M 21.36M 17.79M 15.48M
Net Cash Provided by (Used in) Investing Activities -34.60M -27.58M -33.13M -24.53M -23.01M -52.33M
Net Cash Provided by (Used in) Financing Activities -786.00K 50.71M 65.32M -78.00K -3.62M 3.25M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (OFIX CIK 0000884624), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

PRAX

PRAXIS PRECISION MEDICINES, INC.

AMR

ALPHA METALLURGICAL RESOURCES, INC.

GHC

GRAHAM HOLDINGS CO